p53 nuclear accumulation as an early indicator of lethal prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-08-14

AUTHORS

David I. Quinn, Phillip D. Stricker, James G. Kench, Judith Grogan, Anne-Maree Haynes, Susan M. Henshall, John J. Grygiel, Warick Delprado, Jennifer J. Turner, Lisa G. Horvath, Kate L. Mahon

ABSTRACT

BackgroundAfter radical prostatectomy (RP) for prostate cancer (PC), p53 alterations predict biochemical relapse (BCR), however, recent evidence suggests that metastatic relapse (MR) not BCR is a surrogate for PC specific mortality (PCSM). This updated analysis of a previously published study investigated the association between p53 aberrations, MR and PCSM in men with localised PC.MethodsTwo hundred and seventy-one men with localised PC treated with RP were included. RP specimens stained for p53 by immunohistochemistry were scored as (a) percentage of p53-positive tumour nuclei; and (b) clustering, where ≥12 p53-positive cells within a ×200 power field was deemed ‘cluster positive’. Associations between p53 status and clinical outcomes (BCR, MR and PCSM) were evaluated.ResultsIncreasing percentage of p53-positive nuclei was significantly associated with shorter time to BCR, MR and PCSM (All p < 0.001). Half of the patients were p53 cluster positive. p53 cluster positivity was significantly associated with poorer outcomes at all clinical endpoints (BCR: HR 2.0, 95% CI 1.51–2.65, p < 0.001; MR: HR 4.1, 95% CI 2.02–8.14, p < 0.001; PCSM: HR 12.2, 95% CI 1.6–93; p = 0.016). These associations were independent of other established prognostic variables.Conclusionsp53 aberrations in radical prostatectomy tissue predict clinically relevant endpoints of MR and PCSM. More... »

PAGES

578-583

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41416-019-0549-8

DOI

http://dx.doi.org/10.1038/s41416-019-0549-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1120290334

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31409910


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Nucleus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, p53", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Grading", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms, Castration-Resistant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Protein p53", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Centre, University of Southern California, Los Angeles, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Norris Comprehensive Cancer Centre, University of Southern California, Los Angeles, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St Vincents Prostate Cancer Centre, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "St Vincents Prostate Cancer Centre, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stricker", 
        "givenName": "Phillip D.", 
        "id": "sg:person.01024215217.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024215217.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sydney, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Garvan Institute of Medical Research, Sydney, Australia", 
            "Royal Prince Alfred Hospital, Sydney, Australia", 
            "University of Sydney, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kench", 
        "givenName": "James G.", 
        "id": "sg:person.01251031117.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251031117.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Garvan Institute of Medical Research, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.415306.5", 
          "name": [
            "Garvan Institute of Medical Research, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grogan", 
        "givenName": "Judith", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Garvan Institute of Medical Research, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.415306.5", 
          "name": [
            "Garvan Institute of Medical Research, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haynes", 
        "givenName": "Anne-Maree", 
        "id": "sg:person.01336402541.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336402541.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Union for International Cancer Control, Geneva, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.282968.f", 
          "name": [
            "Union for International Cancer Control, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Henshall", 
        "givenName": "Susan M.", 
        "id": "sg:person.0722075560.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722075560.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St Vincents Hospital, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.437825.f", 
          "name": [
            "St Vincents Hospital, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grygiel", 
        "givenName": "John J.", 
        "id": "sg:person.01142676422.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142676422.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Douglass Hanly Moir Pathology, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.410690.a", 
          "name": [
            "Douglass Hanly Moir Pathology, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delprado", 
        "givenName": "Warick", 
        "id": "sg:person.0627313160.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627313160.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Douglass Hanly Moir Pathology, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.410690.a", 
          "name": [
            "Douglass Hanly Moir Pathology, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Turner", 
        "givenName": "Jennifer J.", 
        "id": "sg:person.01344610217.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344610217.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chris O\u2019Brien Lifehouse, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.419783.0", 
          "name": [
            "Garvan Institute of Medical Research, Sydney, Australia", 
            "Royal Prince Alfred Hospital, Sydney, Australia", 
            "University of Sydney, Sydney, Australia", 
            "Chris O\u2019Brien Lifehouse, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horvath", 
        "givenName": "Lisa G.", 
        "id": "sg:person.01350045111.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350045111.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chris O\u2019Brien Lifehouse, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.419783.0", 
          "name": [
            "Garvan Institute of Medical Research, Sydney, Australia", 
            "Royal Prince Alfred Hospital, Sydney, Australia", 
            "University of Sydney, Sydney, Australia", 
            "Chris O\u2019Brien Lifehouse, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mahon", 
        "givenName": "Kate L.", 
        "id": "sg:person.01241261610.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241261610.77"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature12634", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001644479", 
          "https://doi.org/10.1038/nature12634"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-013-0107-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047592595", 
          "https://doi.org/10.1007/s40265-013-0107-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-08-14", 
    "datePublishedReg": "2019-08-14", 
    "description": "BackgroundAfter radical prostatectomy (RP) for prostate cancer (PC), p53 alterations predict biochemical relapse (BCR), however, recent evidence suggests that metastatic relapse (MR) not BCR is a surrogate for PC specific mortality (PCSM). This updated analysis of a previously published study investigated the association between p53 aberrations, MR and PCSM in men with localised PC.MethodsTwo hundred and seventy-one men with localised PC treated with RP were included. RP specimens stained for p53 by immunohistochemistry were scored as (a) percentage of p53-positive tumour nuclei; and (b) clustering, where \u226512 p53-positive cells within a \u00d7200 power field was deemed \u2018cluster positive\u2019. Associations between p53 status and clinical outcomes (BCR, MR and PCSM) were evaluated.ResultsIncreasing percentage of p53-positive nuclei was significantly associated with shorter time to BCR, MR and PCSM (All p\u2009<\u20090.001). Half of the patients were p53 cluster positive. p53 cluster positivity was significantly associated with poorer outcomes at all clinical endpoints (BCR: HR 2.0, 95% CI 1.51\u20132.65, p\u2009<\u20090.001; MR: HR 4.1, 95% CI 2.02\u20138.14, p\u2009<\u20090.001; PCSM: HR 12.2, 95% CI 1.6\u201393; p\u2009=\u20090.016). These associations were independent of other established prognostic variables.Conclusionsp53 aberrations in radical prostatectomy tissue predict clinically relevant endpoints of MR and PCSM.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41416-019-0549-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "121"
      }
    ], 
    "keywords": [
      "PC-specific mortality", 
      "metastatic relapse", 
      "biochemical relapse", 
      "prostate cancer", 
      "radical prostatectomy", 
      "lethal prostate cancer", 
      "p53-positive nuclei", 
      "p53-positive cells", 
      "p53 nuclear accumulation", 
      "radical prostatectomy tissue", 
      "clinical outcomes", 
      "poor outcome", 
      "clinical endpoints", 
      "specific mortality", 
      "MethodsTwo hundred", 
      "p53 alterations", 
      "p53 aberrations", 
      "prognostic variables", 
      "prostatectomy tissue", 
      "p53 status", 
      "tumor nuclei", 
      "relevant endpoints", 
      "power field", 
      "Recent evidence", 
      "early indicator", 
      "relapse", 
      "cancer", 
      "endpoint", 
      "association", 
      "outcomes", 
      "men", 
      "nuclear accumulation", 
      "prostatectomy", 
      "patients", 
      "aberrations", 
      "immunohistochemistry", 
      "mortality", 
      "percentage", 
      "positivity", 
      "p53", 
      "tissue", 
      "alterations", 
      "nucleus", 
      "status", 
      "cells", 
      "evidence", 
      "short time", 
      "half", 
      "surrogate", 
      "study", 
      "accumulation", 
      "indicators", 
      "variables", 
      "time", 
      "analysis", 
      "clusters", 
      "hundreds", 
      "clustering", 
      "field"
    ], 
    "name": "p53 nuclear accumulation as an early indicator of lethal prostate cancer", 
    "pagination": "578-583", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1120290334"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41416-019-0549-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31409910"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41416-019-0549-8", 
      "https://app.dimensions.ai/details/publication/pub.1120290334"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_822.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41416-019-0549-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0549-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0549-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0549-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0549-8'


 

This table displays all metadata directly associated to this object as RDF triples.

299 TRIPLES      21 PREDICATES      105 URIs      95 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41416-019-0549-8 schema:about N15c6ccdf2d39465496e666a5805fd082
2 N2000bfad002743bdbb2a6fa2d6098af6
3 N2a0bfabbb6b648e59edb0ec8380e78da
4 N2fb9912889304a23aaf83286a85a217e
5 N386e4d57f68b4950b755a6d16b1c4aab
6 N4652e079823442deb0f3a43fb6b5c7de
7 N4860c39461214cf28cec5b9929d1ad56
8 N6dc82f51a7954d34aaddcc52d25cab6e
9 N7984d36706f54d43b811cbd5b7cdab5c
10 N7f81739037fd4628b23b080235e3db73
11 N80fbc24fb34b41b9af3100802bc1d4c9
12 Nbc695ccd3bf74b6aaa7b00259654697a
13 Nc3e2172e7ec64d8dba16409b04ca44cc
14 Nc88067c8011e4bcb85ba9a97c5ac85f6
15 Nd4d252be56c94451aeda779f2d055494
16 Nd607eaf337bb49cbad3ea9101141794d
17 Ne54012e551fa49e193d0696830575e19
18 Nf235446debb34390bf8cd68b01d64281
19 Nfea52e47901e4a6480d7611a009a783c
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author Nde14ec6b87ac40759f8f7eb4ad0a8eb1
23 schema:citation sg:pub.10.1007/s40265-013-0107-2
24 sg:pub.10.1038/nature12634
25 schema:datePublished 2019-08-14
26 schema:datePublishedReg 2019-08-14
27 schema:description BackgroundAfter radical prostatectomy (RP) for prostate cancer (PC), p53 alterations predict biochemical relapse (BCR), however, recent evidence suggests that metastatic relapse (MR) not BCR is a surrogate for PC specific mortality (PCSM). This updated analysis of a previously published study investigated the association between p53 aberrations, MR and PCSM in men with localised PC.MethodsTwo hundred and seventy-one men with localised PC treated with RP were included. RP specimens stained for p53 by immunohistochemistry were scored as (a) percentage of p53-positive tumour nuclei; and (b) clustering, where ≥12 p53-positive cells within a ×200 power field was deemed ‘cluster positive’. Associations between p53 status and clinical outcomes (BCR, MR and PCSM) were evaluated.ResultsIncreasing percentage of p53-positive nuclei was significantly associated with shorter time to BCR, MR and PCSM (All p < 0.001). Half of the patients were p53 cluster positive. p53 cluster positivity was significantly associated with poorer outcomes at all clinical endpoints (BCR: HR 2.0, 95% CI 1.51–2.65, p < 0.001; MR: HR 4.1, 95% CI 2.02–8.14, p < 0.001; PCSM: HR 12.2, 95% CI 1.6–93; p = 0.016). These associations were independent of other established prognostic variables.Conclusionsp53 aberrations in radical prostatectomy tissue predict clinically relevant endpoints of MR and PCSM.
28 schema:genre article
29 schema:isAccessibleForFree true
30 schema:isPartOf N734eca6c2f5e4d4cac79c327f41836c9
31 Nd0b17f1890ee48979f8eac900700d818
32 sg:journal.1017082
33 schema:keywords MethodsTwo hundred
34 PC-specific mortality
35 Recent evidence
36 aberrations
37 accumulation
38 alterations
39 analysis
40 association
41 biochemical relapse
42 cancer
43 cells
44 clinical endpoints
45 clinical outcomes
46 clustering
47 clusters
48 early indicator
49 endpoint
50 evidence
51 field
52 half
53 hundreds
54 immunohistochemistry
55 indicators
56 lethal prostate cancer
57 men
58 metastatic relapse
59 mortality
60 nuclear accumulation
61 nucleus
62 outcomes
63 p53
64 p53 aberrations
65 p53 alterations
66 p53 nuclear accumulation
67 p53 status
68 p53-positive cells
69 p53-positive nuclei
70 patients
71 percentage
72 poor outcome
73 positivity
74 power field
75 prognostic variables
76 prostate cancer
77 prostatectomy
78 prostatectomy tissue
79 radical prostatectomy
80 radical prostatectomy tissue
81 relapse
82 relevant endpoints
83 short time
84 specific mortality
85 status
86 study
87 surrogate
88 time
89 tissue
90 tumor nuclei
91 variables
92 schema:name p53 nuclear accumulation as an early indicator of lethal prostate cancer
93 schema:pagination 578-583
94 schema:productId N4e83ce48c1494bc4abe0dd1b9f570a7b
95 N5b731bd29b304eadb4494f8b1052a7b6
96 Neb97707a83304a6b872a7761c6772fd0
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120290334
98 https://doi.org/10.1038/s41416-019-0549-8
99 schema:sdDatePublished 2022-10-01T06:46
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N424fe1098ca446119a0c824bdfa2e08c
102 schema:url https://doi.org/10.1038/s41416-019-0549-8
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N0cc74f0f2450455a9514c5522805ef1e rdf:first sg:person.01350045111.64
107 rdf:rest N5b4bb070d7e44e2f80a7af784bcec8e7
108 N0f04b60cb32344849d9e7d055e81ac21 rdf:first sg:person.01336402541.45
109 rdf:rest N94e7cdb93daa487790d7c3c032da9e7a
110 N15c6ccdf2d39465496e666a5805fd082 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Tumor Suppressor Protein p53
112 rdf:type schema:DefinedTerm
113 N2000bfad002743bdbb2a6fa2d6098af6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Retrospective Studies
115 rdf:type schema:DefinedTerm
116 N2a0bfabbb6b648e59edb0ec8380e78da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Prostatic Neoplasms, Castration-Resistant
118 rdf:type schema:DefinedTerm
119 N2fb9912889304a23aaf83286a85a217e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Genes, p53
121 rdf:type schema:DefinedTerm
122 N386e4d57f68b4950b755a6d16b1c4aab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Aged
124 rdf:type schema:DefinedTerm
125 N40e6a0e14560470f97916b1168cae3b0 rdf:first N5fe005fbe8654c2a8a1d8f5ad63e9086
126 rdf:rest N0f04b60cb32344849d9e7d055e81ac21
127 N424fe1098ca446119a0c824bdfa2e08c schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 N4652e079823442deb0f3a43fb6b5c7de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Prostatectomy
131 rdf:type schema:DefinedTerm
132 N4860c39461214cf28cec5b9929d1ad56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Middle Aged
134 rdf:type schema:DefinedTerm
135 N4e83ce48c1494bc4abe0dd1b9f570a7b schema:name pubmed_id
136 schema:value 31409910
137 rdf:type schema:PropertyValue
138 N5b4bb070d7e44e2f80a7af784bcec8e7 rdf:first sg:person.01241261610.77
139 rdf:rest rdf:nil
140 N5b731bd29b304eadb4494f8b1052a7b6 schema:name dimensions_id
141 schema:value pub.1120290334
142 rdf:type schema:PropertyValue
143 N5fe005fbe8654c2a8a1d8f5ad63e9086 schema:affiliation grid-institutes:grid.415306.5
144 schema:familyName Grogan
145 schema:givenName Judith
146 rdf:type schema:Person
147 N6dc82f51a7954d34aaddcc52d25cab6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Prostate-Specific Antigen
149 rdf:type schema:DefinedTerm
150 N734eca6c2f5e4d4cac79c327f41836c9 schema:issueNumber 7
151 rdf:type schema:PublicationIssue
152 N7984d36706f54d43b811cbd5b7cdab5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Male
154 rdf:type schema:DefinedTerm
155 N7f81739037fd4628b23b080235e3db73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Cell Nucleus
157 rdf:type schema:DefinedTerm
158 N80fbc24fb34b41b9af3100802bc1d4c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Neoplasm Grading
160 rdf:type schema:DefinedTerm
161 N94e7cdb93daa487790d7c3c032da9e7a rdf:first sg:person.0722075560.52
162 rdf:rest Nc66ed59179394209a39351398e352334
163 Na1157088032c4574b6089af32d3de1b3 rdf:first sg:person.01024215217.05
164 rdf:rest Na8a42a55e83d4c52b3cf3f0f6ce9431b
165 Na8a42a55e83d4c52b3cf3f0f6ce9431b rdf:first sg:person.01251031117.02
166 rdf:rest N40e6a0e14560470f97916b1168cae3b0
167 Nbc695ccd3bf74b6aaa7b00259654697a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Mutation
169 rdf:type schema:DefinedTerm
170 Nc3e2172e7ec64d8dba16409b04ca44cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Neoplasm Staging
172 rdf:type schema:DefinedTerm
173 Nc66ed59179394209a39351398e352334 rdf:first sg:person.01142676422.94
174 rdf:rest Nf857a91c1c8746a08f39a24bd14664a5
175 Nc88067c8011e4bcb85ba9a97c5ac85f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Neoplasm Recurrence, Local
177 rdf:type schema:DefinedTerm
178 Nd0b17f1890ee48979f8eac900700d818 schema:volumeNumber 121
179 rdf:type schema:PublicationVolume
180 Nd4d252be56c94451aeda779f2d055494 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Humans
182 rdf:type schema:DefinedTerm
183 Nd607eaf337bb49cbad3ea9101141794d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Adult
185 rdf:type schema:DefinedTerm
186 Ndb9a115417164817a53751aa13673ab4 rdf:first sg:person.01344610217.03
187 rdf:rest N0cc74f0f2450455a9514c5522805ef1e
188 Nde14ec6b87ac40759f8f7eb4ad0a8eb1 rdf:first sg:person.01013134010.15
189 rdf:rest Na1157088032c4574b6089af32d3de1b3
190 Ne54012e551fa49e193d0696830575e19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Time Factors
192 rdf:type schema:DefinedTerm
193 Neb97707a83304a6b872a7761c6772fd0 schema:name doi
194 schema:value 10.1038/s41416-019-0549-8
195 rdf:type schema:PropertyValue
196 Nf235446debb34390bf8cd68b01d64281 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Prognosis
198 rdf:type schema:DefinedTerm
199 Nf857a91c1c8746a08f39a24bd14664a5 rdf:first sg:person.0627313160.31
200 rdf:rest Ndb9a115417164817a53751aa13673ab4
201 Nfea52e47901e4a6480d7611a009a783c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Prostatic Neoplasms
203 rdf:type schema:DefinedTerm
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
208 schema:name Oncology and Carcinogenesis
209 rdf:type schema:DefinedTerm
210 sg:journal.1017082 schema:issn 0007-0920
211 1532-1827
212 schema:name British Journal of Cancer
213 schema:publisher Springer Nature
214 rdf:type schema:Periodical
215 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
216 schema:familyName Quinn
217 schema:givenName David I.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
219 rdf:type schema:Person
220 sg:person.01024215217.05 schema:affiliation grid-institutes:None
221 schema:familyName Stricker
222 schema:givenName Phillip D.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024215217.05
224 rdf:type schema:Person
225 sg:person.01142676422.94 schema:affiliation grid-institutes:grid.437825.f
226 schema:familyName Grygiel
227 schema:givenName John J.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142676422.94
229 rdf:type schema:Person
230 sg:person.01241261610.77 schema:affiliation grid-institutes:grid.419783.0
231 schema:familyName Mahon
232 schema:givenName Kate L.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241261610.77
234 rdf:type schema:Person
235 sg:person.01251031117.02 schema:affiliation grid-institutes:grid.1013.3
236 schema:familyName Kench
237 schema:givenName James G.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251031117.02
239 rdf:type schema:Person
240 sg:person.01336402541.45 schema:affiliation grid-institutes:grid.415306.5
241 schema:familyName Haynes
242 schema:givenName Anne-Maree
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336402541.45
244 rdf:type schema:Person
245 sg:person.01344610217.03 schema:affiliation grid-institutes:grid.410690.a
246 schema:familyName Turner
247 schema:givenName Jennifer J.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344610217.03
249 rdf:type schema:Person
250 sg:person.01350045111.64 schema:affiliation grid-institutes:grid.419783.0
251 schema:familyName Horvath
252 schema:givenName Lisa G.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350045111.64
254 rdf:type schema:Person
255 sg:person.0627313160.31 schema:affiliation grid-institutes:grid.410690.a
256 schema:familyName Delprado
257 schema:givenName Warick
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627313160.31
259 rdf:type schema:Person
260 sg:person.0722075560.52 schema:affiliation grid-institutes:grid.282968.f
261 schema:familyName Henshall
262 schema:givenName Susan M.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722075560.52
264 rdf:type schema:Person
265 sg:pub.10.1007/s40265-013-0107-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047592595
266 https://doi.org/10.1007/s40265-013-0107-2
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/nature12634 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001644479
269 https://doi.org/10.1038/nature12634
270 rdf:type schema:CreativeWork
271 grid-institutes:None schema:alternateName St Vincents Prostate Cancer Centre, Sydney, Australia
272 schema:name St Vincents Prostate Cancer Centre, Sydney, Australia
273 rdf:type schema:Organization
274 grid-institutes:grid.1013.3 schema:alternateName University of Sydney, Sydney, Australia
275 schema:name Garvan Institute of Medical Research, Sydney, Australia
276 Royal Prince Alfred Hospital, Sydney, Australia
277 University of Sydney, Sydney, Australia
278 rdf:type schema:Organization
279 grid-institutes:grid.282968.f schema:alternateName Union for International Cancer Control, Geneva, Switzerland
280 schema:name Union for International Cancer Control, Geneva, Switzerland
281 rdf:type schema:Organization
282 grid-institutes:grid.410690.a schema:alternateName Douglass Hanly Moir Pathology, Sydney, Australia
283 schema:name Douglass Hanly Moir Pathology, Sydney, Australia
284 rdf:type schema:Organization
285 grid-institutes:grid.415306.5 schema:alternateName Garvan Institute of Medical Research, Sydney, Australia
286 schema:name Garvan Institute of Medical Research, Sydney, Australia
287 rdf:type schema:Organization
288 grid-institutes:grid.419783.0 schema:alternateName Chris O’Brien Lifehouse, Sydney, Australia
289 schema:name Chris O’Brien Lifehouse, Sydney, Australia
290 Garvan Institute of Medical Research, Sydney, Australia
291 Royal Prince Alfred Hospital, Sydney, Australia
292 University of Sydney, Sydney, Australia
293 rdf:type schema:Organization
294 grid-institutes:grid.42505.36 schema:alternateName Norris Comprehensive Cancer Centre, University of Southern California, Los Angeles, USA
295 schema:name Norris Comprehensive Cancer Centre, University of Southern California, Los Angeles, USA
296 rdf:type schema:Organization
297 grid-institutes:grid.437825.f schema:alternateName St Vincents Hospital, Sydney, Australia
298 schema:name St Vincents Hospital, Sydney, Australia
299 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...